TrialThe international journal of neuropsychopharmacology2017

Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder.

Kathryn M Connor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.